支气管扩张剂增强诱导痰提高肺结核诊断效果:NeB-TB随机对照试验
在泰国开展的一项随机对照试验纳入204例疑似肺结核且Xpert MTB/RIF Ultra阴性或痰量不足的成人,比较支气管扩张剂联合3%高渗盐水诱导痰与单用3%高渗盐水。结果显示联合组Xpert MTB/RIF检出率显著更高(30.1% vs 17.8%,RR 1.68,95%CI 1.01-2.80),不良事件更少、诱导尝试次数更少,且启动治疗时间显著更早(中位4.5天 vs 14天,P<.01)。
要点
- 支气管扩张剂增强诱导痰较传统诱导痰显著提高Xpert MTB/RIF检出率(RR 1.68)。
- 联合组不良事件更少、需支气管镜检查趋势更低,早期治疗启动显著更早。
- 门诊亚组获益显著(RR 1.86,95%CI 1.00-3.48)。
核心结论
- 支气管扩张剂增强诱导痰优于传统诱导痰,诊断产出更高、不良事件更少、有创操作更少且结核治疗启动显著更早。
研究设计与样本
- 在泰国King Chulalongkorn Memorial Hospital开展的随机对照试验,2024年7月至10月纳入204例疑似肺结核且Xpert MTB/RIF Ultra阴性或痰量不足的成人。
- 参与者随机分为传统诱导痰组(单用3%高渗盐水,n=101)和支气管扩张剂增强组(雾化支气管扩张剂联合3%高渗盐水,n=103)。
- 主要结局为Xpert MTB/RIF检出结核诊断。
主要发现
- 支气管扩张剂增强组Xpert MTB/RIF检出率为30.1%(NND=4),传统组为17.8%(NND=6),差异12.3%(RR 1.68,95%CI 1.01-2.80)。
- 联合组不良事件更少、诱导尝试次数更少,启动治疗时间显著更早(中位4.5天 vs 14天,P<.01)。
- 门诊亚组获益显著(RR 1.86,95%CI 1.00-3.48)。
关键数值与推荐
- Xpert MTB/RIF检出率:联合组30.1% vs 传统组17.8%,RR 1.68(95%CI 1.01-2.80)。
- 治疗启动中位时间:联合组4.5天 vs 传统组14天(P<.01)。
- 门诊亚组:RR 1.86(95%CI 1.00-3.48)。
临床怎么用
- 对疑似肺结核且Xpert MTB/RIF Ultra阴性或痰量不足的成人,可考虑采用雾化支气管扩张剂联合3%高渗盐水进行诱导痰以提高诊断产出。
- 该策略可能减少支气管镜需求并缩短结核治疗启动时间,尤其在门诊患者中。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Delayed pulmonary tuberculosis (PTB) diagnosis, especially with limited bronchoscopy resources, worsens outcomes and increases transmission risks. Sputum induction offers a noninvasive and effective alternative. We investigated whether adding nebulized bronchodilators improves sputum induction effectiveness for presumed PTB. METHODS: In a randomized controlled trial at King Chulalongkorn Memorial Hospital, Thailand, 204 adults with presumed PTB and negative Xpert MTB/RIF Ultra results or inadequate sputum production were enrolled between July and October 2024. Participants were randomly assigned to conventional sputum induction (3% hypertonic saline alone; n = 101) or bronchodilator-enhanced induction (nebulized bronchodilator plus 3% hypertonic saline; n = 103). The primary outcome was TB diagnosis by Xpert MTB/RIF assay. RESULTS: Tuberculosis detection rates by Xpert MTB/RIF were significantly higher in the bronchodilator-enhanced group (30.1%; number needed to diagnose [NND] = 4) versus the conventional group (17.8%; NND = 6), with a 12.3% difference (relative risk [RR], 1.68; 95% confidence interval [CI] 1.01-2.80). The group receiving bronchodilator co-administration showed a trend toward higher mycobacterial culture positivity (RR 1.49; 95% CI .93-2.41) and a lower need for bronchoscopy (RR 0.41; 95% CI .15-1.12). They also experienced fewer adverse events and required fewer induction attempts, significantly assisting us to be able to provide early treatment to the patients (median 4.5 vs 14 days; P < .01). Subgroup analysis revealed a significant benefit among outpatients (RR 1.86; 95% CI 1.00-3.48). CONCLUSIONS: Bronchodilator-enhanced sputum induction demonstrated superiority over conventional induction, with higher diagnostic yield, fewer adverse events, fewer invasive procedures, and significantly earlier TB treatment initiation, supporting its potential as a new standard for TB diagnosis. CLINICAL TRIALS REGISTRATION: Thai Clinical Trials Registry (TCTR20240709001), registered on 9 July 2024.
引用
- Mingchay P, Kawkitinarong K, Torvorapanit P, et al. Effectiveness of Nebulized Bronchodilator-Enhanced Sputum Induction in Thai Patients With Presumed Pulmonary Tuberculosis: A Randomized Controlled Trial (NeB-TB Trial). Clin Infect Dis. 2026. PMID: 41125243. doi:10.1093/cid/ciaf580
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。